European Virtual Human Twin
EDITH is a Coordination and Support Action (CSA), funded by the European Commission, which will capitalise on the developments of digital technologies, high-performance computing, availability and access to research and healthcare data in Europe, with the mission of defining a roadmap to go from separated single organ systems, to data-driven and knowledge-driven fully integrated multiscale and multiorgan whole-body twin. EDITH will facilitate this process by building an evolutionary ecosystem, driven by a consensus among the relevant European communities, and implemented through the aid of practical tools, such as a data/model repository (within the scope of EDITH), and a simulation platform (to be implemented after EDITH).
In Silico World: Lowering barriers to ubiquitous adoption of In Silico Trials
The In Silico World project aims at accelerating the uptake of modelling and simulation technologies used for the development and regulatory assessment of medicines and medical devices, by lowering seven identified barriers: development, validation, accreditation, optimisation, exploitation, information, and training. Our vision is a future where medical products, thanks to the use of modelling and simulation, are developed much faster and with the highest possible safety standards.
Simulation of Cardiac Devices & Drugs for in-silico Testing and Certification
SimCardioTest aims to design new predictive tools in cardiac pathologies and aims to accelerate the uptake of computer simulations for testing medicines and medical devices. One objective is to provide a framework and wide approach of in-silico methods (computer modelling and simulation) where generic and standardized elements can be used for other applications. The second one aims to demonstrate that such approach can help develop devices and drugs as well as reduce the cost and time to market and gain the trust of scientists, companies, regulatory bodies, physicians, and patients. The final objective is to impact the whole clinical trials, since this approach can replace some invasive aspects of these trials, and maybe provide novel biomarkers for more accurate clinical trials.
In-silico development and clinical trial platform for testing in-situ tissue engineered heart valves
SimInSitu promises the first in-silico clinical trial platform to predict the short- and long-term response of in-situ tissue engineered heart valves (TEHV) in humans. We will enable the simultaneous assessment and optimization of the performance and safety of TEHV by a multidisciplinary approach combining advanced patient-specific computational models, tissue and growth remodelling algorithms, and dedicated device models. SimInSitu will not only develop computer models but will also verify and validate them thoroughly by making use of in-vitro and in-vivo data and, where necessary, will generate new data to support the credibility of in-silico clinical trials.